Editor's Corner

Cancer Genetics makes strides in $14M deal for Response Genetics

Cancer Genetics got approval from a U.S. bankruptcy court in Delaware to purchase Response Genetics, almost two months after the company emerged as the highest bidder in an auction sale of Response's long-beleaguered business.

Illumina expands in China with cancer Dx deal

Illumina is joining forces with China's Amoy Diagnostics to create next-generation sequencing cancer tests for the Chinese clinical market, expanding its footprint in the country while strengthening its commitment to developing innovative technology for the disease.

Quest's Focus Diagnostics gets FDA clearance to add additional strains to its flu test

Focus Diagnostics, a unit of Quest Diagnostics, announced that it has the FDA's 510(k) clearance for its Simplexa Flu A/B & RSV Direct Kit for 46 additional influenza A and B virus strains and 7 additional respiratory syncytial virus strains.

Illumina stock tanks after profit warning

Illumina issued a profit warning due to poor sales of its NextSeq Series Desktop Sequencer as well as weakness in Europe and Japan, sending its stock tumbling 10% for the day. The company expects earnings per share to fall below consensus expectations, consistent with a 3% revenue shortfall.

Quest and Inovalon launch patient analytics tool for healthcare providers

Quest Diagnostics has been working hard to diversify its offerings, beefing up its presence in diagnostics as it delivers on plans for growth. In its latest move, the company is teaming up with health IT outfit Inovalon to roll out a cloud-based analytics platform for healthcare providers.


From Our Sister Sites


San Francisco's Symic raised $25 million to fund its work on a pair of anti-inflammatory medicines targeting the extracellular matrix, recruiting Eli Lilly to lead the round as it works through clinical development.


UniQure has dropped plans to seek FDA approval for its €1.1 million ($1.2 million)-per-course gene therapy Glybera. The decision comes three months after FDA told uniQure it would need to see data from two clinical trials of the lipoprotein lipase deficiency therapy before making a decision.